The frequency of tumour-infiltrating CD4+TIGIT+ cells and CD8+PD-L2+cells positively correlated with a poor response to subsequent neoadjuvant treatment determined by tumour regression grade (p = 0.04 and p = 0.03) (Fig.1S). This evidence concerns the gene PDCD1LG2 and neoplasm.